“…Although it has been indicated that VEGF could be a good marker for determining the risk of developing CRC and could be used as a therapeutic target for new molecular anticancer drugs (Hanrahan et al, 2003;Fernando and Hurwitz, 2004;Dassoulas et al, 2009;Vidaurreta et al, 2010), the data remain conflicting if VEGF gene polymorphisms are associated with the prognosis of CRC (Yamamori et al, 2004;Park et al, 2007;Bae et al, 2008;Maltese et al, 2009;Wu et al, 2009;Hansen et al, 2010b;Antonacopoulou et al, 2012;Jang et al, 2013b). Therefore, to test this hypothesis, we investigated possible associations between genetic variations at the -2578A > C, + 936C > T, and -460C > T polymorphic site in the VEGF gene, in patients who have had CRC compared to healthy individuals.…”